El Badri S, Tahir B, Balachandran K, et al. - In the real-world older population, palbociclib affords an effective as well as a well-tolerated treatment option for breast cancer. Low levels of clinically significant toxicities were observed with palbociclib. Decision making in these patients can be aided by geriatric and frailty assessments.

• A national UK retrospective study of 276 estrogen receptor-positive/human epidermal growth factor receptor 2 negative-advanced breast cancer patients aged ≥75 years treated with palbociclib + aromatase inhibitor (AI) in the first line setting.

• Low incidence (2.2%) of febrile neutropenia, and a clinical benefit rate of 87% was reported.

• Higher rates of treatment discontinuation and dose reductions were documented.

• Progression-free survival (PFS) rates were 75.9% and 64.9% and overall survival rates were 85.1% and 74.0% at 12- and 24- months, respectively.

• Dose delays and decreases were not related to a worse survival outcome.

• PFS and development and severity of neutropenia were predicted by Age-adjusted Charlson Comorbidity Index.